OCUPHIRE PHARMA
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage cl... inical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
OCUPHIRE PHARMA
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2018-02-01
Address:
Farmington Hills, Michigan, United States
Country:
United States
Website Url:
http://www.ocuphire.com
Total Employee:
1+
Status:
Active
Contact:
(248) 681-9815
Email Addresses:
[email protected]
Total Funding:
24.56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon ReCAPTCHA Cloudflare Cloudflare Network Error Logging Cloudflare SSL ReCAPTCHA V2 CloudFront
Similar Organizations
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-06-17 | Rexahn Pharmaceuticals | Rexahn Pharmaceuticals acquired by Ocuphire Pharma | N/A |
Investors List
Altium Capital
Altium Capital investment in Post-IPO Equity - Ocuphire Pharma
Lincoln Park Capital Fund
Lincoln Park Capital Fund investment in Post-IPO Equity - Ocuphire Pharma
Ayrton Capital
Ayrton Capital investment in Post-IPO Equity - Ocuphire Pharma
District 2 Capital
District 2 Capital investment in Post-IPO Equity - Ocuphire Pharma
National Eye Institute
National Eye Institute investment in Grant - Ocuphire Pharma
Biosciences Research and Commercialization Center (BRCC)
Biosciences Research and Commercialization Center (BRCC) investment in Seed Round - Ocuphire Pharma
Blue Water Angels
Blue Water Angels investment in Seed Round - Ocuphire Pharma
Michigan Angel Fund
Michigan Angel Fund investment in Seed Round - Ocuphire Pharma
First Capital Fund
First Capital Fund investment in Seed Round - Ocuphire Pharma
BELLE Capital
BELLE Capital investment in Seed Round - Ocuphire Pharma
Official Site Inspections
http://www.ocuphire.com Semrush global rank: 2.23 M Semrush visits lastest month: 8.64 K
- Host name: 172.67.133.251
- IP address: 172.67.133.251
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
